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Abstract
Objective Timely screening for hyperglycaemia in pregnancy using a simple glucose test enhances early detection and 
control of gestational diabetes mellitus (GDM). The aim of this study was to provide an overview of the evidence on the 
cost-effectiveness of identification and/or treatment of GDM.
Methods We conducted a systematic review using three electronic databases (PubMed, EMBASE, and Cochrane) of cost-
effectiveness studies of GDM screening and treatment published during 2000–2017.
Results The initial search discovered 287 references (PubMed 86, EMBASE 195, Cochrane library 6) of which six full 
articles were included in the review. Two articles were model-based analysis and the remaining four were trial based. Two 
studies demonstrated favorable cost-effectiveness of intensified management of mild GDM. In the other included studies, 
neither screening nor treatment of GDM was shown to be cost effective, although results varied with the particular outcome 
measures used and the assumptions that where applied.
Conclusion Neither screening nor treating GDM seems to be convincingly cost-effective from the studies reviewed. However, 
all studies were done in high-income countries with obviously different health systems than low-/middle-income countries 
(LMIC) have. Since detection of GDM may be relatively poor in LMIC, screening might be more worthwhile in these coun-
tries. Comprehensive research is necessary in LMIC, including the potential outcomes of assessing its cost-effectiveness. 
Favorable cost-effectiveness could help in bridging the need for and access to increased diabetes screening in early pregnancy 
in these countries.
Keywords Hyperglycemia in pregnancy · Gestational diabetes mellitus · Cost-effectiveness
Introduction
An increased blood glucose level (92–125  mg/dl) first 
detected at any time during pregnancy is classified as ges-
tational diabetes mellitus (GDM) as part of hyperglycemia 
in pregnancy (HIP), which is any kind of increased blood 
glucose level during pregnancy, including live births in 
women with known diabetes [1]. The distinction between 
HIP and GDM has only recently (2013) been made by the 
World Health Organization (WHO) [2]. See supplementary 
Appendix 1 for an overview of the WHO classification.
The International Diabetes Federation (IDF) estimates 
that 21.4 million (16.8%) of women who gave live birth in 
2013 had some form of HIP. There are some regional differ-
ences in the prevalence of HIP. The Southeast Asian Region 
had the highest crude incidence of the HIP at 23.1% of live 
births, followed closely by the Middle East and North Afri-
can Region with 22.3% [3]. A staggering 91.6% of cases of 
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the HIP were in low- and middle-income countries (LMIC). 
Estimates of GDM by region according to the diabetes atlas 
range from 10.4 to 25.0%, where North America-Caribbean 
is the lowest and Southeast Asia is the highest [1, 3]. Aware-
ness of HIP as a risk factor and access to maternal care in 
LMIC are often limited.
GDM can significantly affect the health of both mother 
and child. A pregnant woman with diabetes can experi-
ence pre-eclampsia, infections, obstructed labor, and post-
partum hemorrhage compared to women without diabetes 
[4–6]. These pregnant women with diabetes are also at risk 
of long-term complications associated with diabetes, such 
as retinopathy, nephropathy, and neuropathy [7, 8]. For the 
fetus, GDM is associated with stillbirth, preterm birth, mac-
rosomia, growth retardation and congenital anomalies [9]. 
According to the American Diabetes Association, women 
with GDM should be screened for persistent diabetes at 
6–12 weeks postpartum, and subsequently every 1–3 years 
[10]. An estimated 30–50% of women with a history of ges-
tational diabetes develops it again in subsequent pregnancies 
within 5–10 years, and half of these women progress into 
type 2 DM [11]. Also, babies born from diabetic pregnan-
cies are at increased risk of developing, for instance, juve-
nile obesity, metabolic disorders in adolescence and type 2 
DM in adulthood [12]. The primary goal of managing all 
types of GDM is to create and maintain a normal blood glu-
cose level for both the mother and fetus and also to prevent 
miscarriages and stillbirths [13–15]. GDM can be managed 
in many ways, for instance, using nutritional management, 
insulin treatment, or oral hypoglycemic agents [16–18]. 
According to the guidelines mentioned above, insulin is the 
first line of pharmacologic therapy.
Published data from IDF describe the majority of GDM 
screening is conducted in high-income countries (HIC) 
mainly in Europe and North America and Caribbean [3]. 
However, as the screening methodology used in HIC is more 
elaborate than commonly performed in LMIC, the evidence 
on GDM screening from HIC cannot be extrapolated to 
LMIC. Therefore, more data on screening for GDM in LMIC 
are needed to support the case for universal screening.
Treating the short- and long-term complications of GDM 
can be costly. Costs of treatment for perinatal complications 
in the United States may be up to US$9000 during the first 
year of life [19], and costs of treatment for T2DM can aver-
age up to US$3500 per year [20]. All strategies to reduce 
GDM require investments up front, and it should be deter-
mined whether these are worthwhile [21]. Cost-effectiveness 
analysis (CEA) compares the cost and effects of at least two 
strategies or interventions [22]. The outcome of a cost-effec-
tiveness analysis is often an incremental cost-effectiveness 
ratio (ICER), which expresses the additional investments 
required to gain one additional unit of effect. Effects can be 
some measure of health such as the number of births at term, 
perinatal deaths prevented, or increased baby weight. In par-
ticular, quality-adjusted life years (QALYs) are often used 
[23, 24]. There have been many effectiveness trials but fewer 
cost-effectiveness studies in GDM. The objective of the pre-
sent study is to provide, by means of a literature review, an 
overview of the existing evidence on the cost-effectiveness 
of identification and/or treatment of GDM.
Methods
Study design and search strategy
We conducted a literature review of cost-effectiveness stud-
ies related to gestational diabetes mellitus published between 
2000 and 2017, taking into account reporting guidelines of 
preferred reporting items for systematic reviews and meta-
analyses (PRISMA) diagram [25]. We decided to only 
include papers published from 2000 onwards as this is the 
first year after the diagnostic criteria for GDM were for-
mally stated in 1999. We accessed three electronic databases 
(PubMed, EMBASE, and Cochrane) in August 2017. Sup-
plementary Appendix 1 shows details of the search terms. 
We only included studies that were performed in pregnant 
women and that were written in English.
Study selection and data extraction
The search results were downloaded into RefWorks Web-
Based Bibliographic Management Software. From the ini-
tial search results, duplicates were removed, and title and 
abstract were screened. Articles that were not cost-effective-
ness studies, not full papers (e.g., conference proceedings), 
or not on the topic of GDM were excluded. Alongside the 
data extraction, we converted cost estimates into a single 
currency (international $) and price year (2016), with the 
purpose of facilitating comparison of estimates collected 
from different studies. This conversion was performed using 
Organisation for Economic Co-operation and Development 
(OECD) Consumer Price Index and Purchasing Power Pari-
ties (PPPs) [26, 27].
Quality of reporting
The Consolidated Health Economic Evaluation Report-
ing Standards (CHEERS) statement was used as a check-
list to rate the quality of reporting in the included papers. 
The CHEERS statement of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 
Health Economic Evaluation Publication Guidelines Good 
Reporting Practices Task Force is a guideline intended to 
improve reporting of economic evaluation [28, 29]. Within 
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the CHEERS statement, a 24-item checklist is available to 
examine the quality of reporting of health economic studies.
Risk of bias assessment
The recommended approach to assess risk of bias in reviews 
of cost-effectiveness studies is by means of the Consensus 
Health Economics Criteria (CHEC)-extended checklist [30, 
31]. We chose to use a version that was adapted for specific 
use in diabetes mellitus type 2 (DMT2), as described in a 
study by Odnoletkova et al. [32]. This risk of bias approach 
was summarized using the Review Manager software.
Results
Systematic search strategy
The database search discovered 287 references (PubMed 86, 
EMBASE 195, Cochrane library 6), of which 274 were left 
after deduplication (see Fig. 1 for a flow diagram). Screen-
ing of the title and the abstract found that 223 articles had a 
topic other than GDM, 36 articles were not cost-effective-
ness studies, and 6 articles were not written in English. By 
this screening, nine articles met the inclusion criteria. Four 
of these articles were conference proceedings for which no 
full papers were available. Therefore, a final set of six pub-
lications was included in the study [33–38].
Data extraction
An overview of the main study characteristics of the six 
included cost-effectiveness studies is provided in Table 1. 
Table 2 shows information on categories of included costs, 
currency and price year.
Four of the included studies were trial-based economic 
evaluations and two were model based. All trial-based stud-
ies in this review used intention-to-treat analysis. Clinical 
trials that use intention-to-treat analysis may be a reliable 
source for an economic evaluation, as they approximate real-
world clinical practice better than per-protocol analyses [22]. 
Moss et al. compared dietary advice, blood glucose monitor-
ing and insulin therapy as needed to routine pregnancy care 
in a population diagnosed with mild GDM [33]. Kolu et al. 
investigated the effect of lifestyle counseling compared to 
standard care among women at risk for GDM within 7 years 
of follow-up [36]. This study continued until 7 years of fol-
low-up with half of the participants still included and the 
Fig. 1  Flow of search strategy 
in systematic review 287 records screened 
PubMed: 86 
EMBASE: 195 
Cochrane library: 6 
13 duplicates 
274 records after deduplication 
Title and abstract screening 
Different topic : 223 
Not cost-effectiveness study : 36 
Articles not written in English : 6 
9 records after title and abstract 
screening 
Full text screening 
Conference proceedings : 4 
5 full articles included 
6 full articles included 
Snowballing 
1 full article included 
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children who were born during the initial study [37]. Oost-
dam et al. also compared lifestyle counseling and scheduled 
exercise (FitFor2) in pregnant women at increased risk for 
GDM. Women in the control group were not presented the 
FitFor2 program and received care as usual [35].
All trial-based studies included reported an ICER for 
various outcome measures, e.g., birth at term, perinatal 
complications prevented, reduced birth weight in offspring, 
and QALYs. Moss et al. reported the ICER to be I$13,886 
per-severe perinatal complication prevented and I$30,549 
per perinatal death prevented. Even though fewer babies 
experienced perinatal complications and death, more women 
were induced into labor. Moss et al. also presented a long-
term analysis based on simple extrapolation of the perinatal 
deaths prevented into life years gained. The incremental cost 
per life year gained was I$1508.65 which was considered 
to be highly cost effective. Kolu et al. present an ICER of 
I$9.27 for each additional gram of birth weight avoided. This 
intervention was effective in reducing birth weight, but also 
more expensive compared to usual care. After the 7-year 
follow-up, 70% of total costs in the population were due to 
absence from work. The intervention was not cost effective 
in terms of QALYs gained but still cost effective for absence 
from work with an ICER of −I$258 per day of absence from 
work prevented, indicating the dominance of the interven-
tion as both costs were saved and absence from work was 
reduced.
In the study by Oostdam et al., the total cost in the inter-
vention group was higher than for standard care because 
of prolonged hospitalization and a higher rate of preterm 
births in this group. This also caused a slight decrease 
in QALYs in the intervention group, implying the inter-
vention was inferior, i.e., more costly and less effective, 
compared to standard care. Oostdam et al. also present an 
analysis on birth weight, which led to comparable results 
in the sense that most simulated cost-effectiveness pairs 
were in the northwest quadrant of the cost-effectiveness 
(CE) plane, so Fitfor2 was also considered inferior when 
it concerned reducing birth weight.
The study by Farrar et al. used a meta-analysis and 
modeling approach for the economic evaluation. They 
compared four strategies for testing and treating for hyper-
glycemia in healthy pregnancies. Their main results indi-
cated that for the base case as well as for all scenarios 
analyses, the most cost-effective strategy at a £20,000 
(I$33,573) threshold was ‘no screening/testing or treat-
ment’. It is only with the inclusion of maternal longer term 
health outcomes and at cost-effectiveness thresholds of 
£24,000 (I$40,288) per QALY that net health benefits were 
improved by intervening. Ohno et al. also reported on a 
model-based study, comparing nutritional counseling, diet 
therapy plus insulin if required with usual prenatal care 
in women diagnosed with mild GDM [34]. The outcome 
for the economic evaluation was the sum of maternal and 
neonatal QALYs. Costs were also calculated from both the 
maternal and neonatal perspective, though only short-term 
events, i.e., related to pregnancy and delivery, were taken 
into account. Results indicated that treating GDM would 
be more expensive and more effective with an ICER of 
$20,412 per additional QALY, which was considered to 
be well below the threshold.
Table 2  Cost categories which are taken into account in the included cost-effectiveness analysis study
Study Categories of included costs Currency, year
Moss [33] Direct costs: antenatal clinic visits, specialist clinic visits, dietician visits, diabetes educator, blood 
glucose monitoring equipment, and insulin therapy
Indirect costs: charges to the family: paid child care, travel, food substitution, mother time off paid 
work, and partner time off work
Australian dollars, 2002
Ohno [34] Direct cost: pharmacotherapy, antenatal visits, ancillary diabetes-related visits, and antepartum fetal 
surveillance
US dollars, 2009
Oostdam [35] Direct costs: general practitioner, medical specialist, hospitalization, occupational physician, mental 
health care, paramedical, dietician, midwife, obstetrician, delivery, and medications
Indirect cost: productivity loss
Euro, 2009
Kolu [36] Direct costs: laboratory test cost, health care visit cost, insulin/diabetes medication cost, delivery cost, 
hospital days cost, neonatal care cost, and costs of healthcare intervention: supplemental public 
health nurse’s contribution
Indirect cost: Productivity loss
Euro, 2009
Kolu [37] Direct costs: occupational health care, primary care doctor, special health care doctor, registered nurse, 
maternity clinic, family planning clinic, physiotherapist, and inpatient days in special health care
Indirect cost: productivity loss
EUR, 2015
Farrar [38] Direct costs: screening and diagnostic testing costs, adverse perinatal outcomes, treatment costs, and 
intensive lifestyle intervention costs
British Pounds, 2014
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Quality of reporting assessment
For each study, report on all 24 items in the CHEERS 
checklist is provided in the supplementary Appendix. 
Most of the studies reported quite comprehensively in the 
sense that they provide information on almost all items 
on the checklist. Moss et al. performed a trial-based eco-
nomic evaluation and reported to have used bootstrap-
ping to confirm their analysis. There is no report of the 
bootstrapping results, though, while an incremental cost-
effectiveness plane or cost-effectiveness acceptability 
curve would have been informative as to the uncertainty 
surrounding outcomes.
Risk of bias
Figure 2 shows the summary information for risk of bias 
per study. It should be noted that for studies that were trial 
based, providing a model description was not applicable, 
so the absence of a description does not cause any bias. 
Also, when using a time frame for analyses of less than 
1 year, discounting is not needed.
For trial-based economic analyses in gestational-based 
analyses, a follow-up from the early pregnancy until 
delivery that took less than 1 year would not be a problem 
in terms of discounting. Although Kolu et al. performed 
a long-term follow-up, they did not discount costs nor 
health effects. When they would have discounted future 
costs and health, the ICERs might have been impacted, 
although it is difficult to say in which direction.
The treatment estimates from Farrar were sourced 
from pooled RCT data of studies performed in HIC and, 
therefore, could likely validly be generalized to the UK 
obstetric population with GDM. In general, there were no 
serious structural sources or concerns for bias.
Discussion
The inclusion criteria that we stated at the beginning of this 
study resulted in six articles included. The studies included 
in this review were exclusively located in high-resource 
countries. This is probably due to the fact that screening for 
GDM is common in these countries, as opposed to LMICs 
where screening programs are in the start-up phase, at best, 
and, therefore, economic evaluations are not yet in question.
In the studies included, several terms were used to 
describe standard care; standard practice, routine care and 
standard care itself. Their content could be different accord-
ing to local guidelines in each hospital or study site. Dif-
ferences in how standard care was defined and provided 
hamper comparison between the cost-effectiveness results 
of the included studies. The primary outcome of all studies 
was well defined.
In the countries and settings for which the economic 
evaluations were performed, maternity services and guide-
lines on screening and treatment of GDM were already well 
established. Pregnant women who were considered to be at 
a certain risk for GDM would have an HbA1c screening at 
24–28 weeks of gestation [39]. A study by Jiwani in 2011 
showed that more than 80% of countries that do not provide 
any GDM-related maternity care was LMIC [39]. They con-
clude that many of these countries have limited healthcare 
services capacity and do not yet have standardized practices 
for GDM screening and management.
Taking the evidence from all six papers together, it seems 
that treatment of GDM in itself may be effective, but screen-
ing the whole population for GDM and subsequently treat 
is not likely to be cost effective. According to Farrar et al. 
this is caused by the fact that the health benefits gained by 
treatment do not outweigh the investments needed to screen 
the whole population of pregnant women [38]. The unfa-
vorable cost to benefit ratio may be a consequence of the 
fact that most GDM cases would, at a certain point, already 
Fig. 2  Risk of bias for each item 
of the modified CHEC-extended 
checklist
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be detected with care as usual and active screening does 
not significantly add to that. In this case then ‘no screen-
ing/testing or treatment’ is the cost-effective option at the 
considered range of cost-effectiveness thresholds [38]. 
Based on the small number of studies and sample sizes, the 
impact of screening women for GDM on health outcomes is 
inconclusive. The most commonly observed risk factors are 
age ≥ 30 years and family history of type 2 diabetes mellitus 
[38, 40]. However, in LMIC, the situation may be different. 
In LMIC the regimen of pregnancy checkups is less strict 
and occasional or regular detection of GDM may, therefore, 
be an exception. In this kind of situation, the added value of 
protocolized screening, as advocated by health authorities, 
would be higher.
One more reason for the somewhat disappointing cost-
effectiveness of interventions directed toward GDM manage-
ment might be that in all trial-based studies in this review, 
low compliance and high drop-out was a problem. As Oost-
dam et al. put it, ‘many women stopped exercising during the 
period of their pregnancy because of physical (pregnancy-
related) limitations’ [35]. As it seems that the low compli-
ance is intrinsic to the intervention and the pregnant popula-
tion, it is unlikely that real-world cost-effectiveness would 
be better than reported from these trials.
Drawing conclusions from the included studies was dif-
ficult because of a number of reasons. First, the cost-effec-
tiveness results were not always reported clearly and com-
prehensively. For instance, in the absence of an incremental 
cost-effectiveness plane, one has to very carefully check the 
results to see whether a negative ICER is the result of nega-
tive effects and positive costs, or the other way around, and 
when the outcome measure is expressed as ‘the less the bet-
ter’ this complicates things even more. Furthermore, not all 
of the articles reviewed presented QALYs. Notably, the cost-
effectiveness of screening or treatment is ideally reported 
in the way Ohno et al. have done [34], i.e., in terms of cost 
per QALY over the whole lifetime of both mother and child. 
The wide variety of outcome measures used in the included 
studies, even though perfectly relevant from a clinical point 
of view, adds to the inconclusiveness.
Strengths and limitations
This is the first review to provide integrated evidence on 
cost-effectiveness in gestational diabetes. Next to summariz-
ing results according to guidelines for systematic reviews of 
economic evaluation from van Mastrigt [30], we explicitly 
reported the risk of bias for all included studies. Combining 
trial- and model-based studies together in one table provides 
one integrated presentation, comparison and interpretation 
of the cost-effectiveness results. A definite limitation of 
this review is that some of the interventions investigated 
in the included studies were not yet proven to be clinically 
effective. Therefore, this review should not be used to con-
clude on the clinical effectiveness of therapeutic interven-
tions, but rather be used to illustrate the potential favorable 
cost-effectiveness of interventions in gestational diabetes.
Future research
While most countries can afford the investments needed, 
the poorest nations will need assistance to reach the tar-
gets. Even though WHO already provided the new screening 
approach, a standard estimation is still needed, as well as 
making cost-effectiveness analysis more generalizable to the 
LMIC. Since the sustainable development goals put attention 
on universal health coverage of reproductive, maternal, new-
born and child health including service capacity and access, 
future research on this topic is warranted.
Conclusion
From the included studies, GDM treatment could be con-
sidered cost effective under certain circumstances, but uni-
versal screening for GDM does not seem worthwhile. All 
studies in this review were done in high-income countries. 
Since regular detection of GDM is potentially poor in LMIC, 
the findings of this systematic review do not apply to an 
LMIC setting, and screening might be worthwhile in these 
countries. The decision on the best strategy for screening, 
diagnosis, and management should be made based on cost, 
availability, and accessibility of the local existing health 
facilities. Further research is warranted to assess applica-
bility and cost-effectiveness concerning GDM especially in 
resource-limited countries of the world.
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